Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

The published data showed that the combination of avutometinib plus defactinib demonstrated a confirmed overall response rate of 31% in all patients with recurrent low-grade serous ovarian cancer ...

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the most promising stocks according to Wall Street analysts. On June 23, Revolution Medicines announced that the US FDA granted Breakthrough Therapy ...

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...

She’s at her pre-K promotion ceremony—but her joy isn’t for herself. It’s for her classmate, who is neurodivergent and ...

In combination with a KRAS inhibitor, HotSpot’s CBM signalosome inhibitor achieved complete suppression of downstream signalling in KRASG12X cell lines. HotSpot’s CBM signalosome inhibitor ...

Jazz Pharmaceuticals has paid $10m upfront for a KRAS inhibitor programme from UK biotech Redx Pharma that extends its targeted cancer therapy pipeline.

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

SEBI's accredited investor framework, introduced in 2021, aims to provide sophisticated investors with access to exclusive ...

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.